Loading clinical trials...
Loading clinical trials...
Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349
Conditions
Interventions
rifapentine
rifapentine and moxifloxacin
+1 more
Locations
33
United States
TBTC Site 82/ ACTG Site 801 USCF AIDS CRS
San Francisco, California, United States
TBTC Site 24 Columbia Unversity
New York, New York, United States
TBTC Site 20 UNTHSC (University of North Texas Health Science Center)
Fort Worth, Texas, United States
TBTC Site 62 Baylor College of Medicine & Affiliated Hospitals/VA
Houston, Texas, United States
TBTC Site 63 San Antonio VA Medical Center (South Texas Group)
San Antonio, Texas, United States
TBTC Site 94/ ACTG Site 12201 Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Start Date
January 25, 2016
Primary Completion Date
July 1, 2020
Completion Date
May 1, 2021
Last Updated
December 4, 2024
NCT06192160
NCT05947890
NCT05989802
NCT06272812
NCT02354014
NCT07303699
Lead Sponsor
Centers for Disease Control and Prevention
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions